From the Guidelines
Quello allergy drops can be an effective treatment option for some individuals with allergies, as supported by the most recent and highest quality study 1. These sublingual immunotherapy (SLIT) drops work by gradually exposing your immune system to small amounts of allergens, helping it build tolerance over time. Treatment typically involves daily drops under the tongue for 3-5 years, with some people experiencing improvement within a few months. Quello specifically offers personalized formulations based on allergy testing. The drops contain diluted versions of allergens like pollen, dust mites, or pet dander. While generally safe with fewer severe reactions than allergy shots, they may cause mild side effects like mouth itching or stomach discomfort. Effectiveness depends on consistent use and proper allergen identification. For best results, Quello drops should be used as directed by your healthcare provider as part of a comprehensive allergy management plan that may include environmental controls and other medications as needed.
Key Points to Consider
- The most recent study 1 provides high-quality evidence supporting the effectiveness of AIT in achieving symptom control in the treatment of allergic rhinitis.
- AIT has been shown to improve symptoms and quality of life while reducing rescue medication intake in patients with allergic rhinitis and/or allergic asthma.
- The treatment duration for AIT is typically 3-5 years, with some patients experiencing improvement within a few months.
- Quello allergy drops are a form of SLIT, which has been shown to be effective in patients sensitized to specific allergens.
- Proper allergen identification and consistent use are crucial for the effectiveness of Quello allergy drops.
Potential Benefits and Risks
- Benefits: improved symptom control, reduced medication use, potential prevention of new allergic sensitizations, and continued benefit after cessation of therapy.
- Risks: mild side effects like mouth itching or stomach discomfort, potential for local reactions.
- According to the study 1, clinicians should educate patients about the potential benefits and risks of AIT, including the differences between SCIT and SLIT.
Clinical Recommendations
- Quello allergy drops should be considered as a treatment option for patients with allergic rhinitis and/or allergic asthma who have inadequate control of symptoms with medical therapy, allergen avoidance, or both, or who have a preference for immunomodulation 1.
- Clinicians should discuss AIT options with their patients and document these discussions in the medical record.
- Patients should be educated about the potential benefits and risks of AIT, and the importance of consistent use and proper allergen identification.
From the Research
Allergy Drops Efficacy
- The provided studies do not specifically mention "quello allergy drops" but discuss sublingual immunotherapy (SLIT) and its efficacy in treating allergic rhinitis and asthma 2, 3, 4, 5, 6.
- SLIT has been shown to be a safe and effective treatment for allergic rhinitis, with benefits including decreased symptoms and medication use 3.
- Studies have compared the efficacy of SLIT to subcutaneous immunotherapy (SCIT) and pharmacotherapy, with results indicating that SLIT is a viable alternative to these treatments 2, 4, 5, 6.
Comparison to Other Treatments
- A systematic review and indirect comparison of SCIT and SLIT found that both treatments were effective in reducing symptoms of seasonal allergic rhinitis, but the study was unable to conclusively determine which treatment was more effective 5.
- A pooled analysis of SLIT-tablet trials and pharmacotherapy trials found that SLIT-tablets had a greater effect on nasal symptoms than some pharmacotherapies, such as montelukast and desloratadine, for seasonal and perennial allergic rhinitis 6.